AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36350359 — intervention group
Group type: EXPERIMENTAL
Intervention: Total vitamin D intake from food and supplements
Number of subjects: 265
Study 36350359 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D (S-25(OH)D) levels
Number of subjects: 265
Study 36350362 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy Device
Number of subjects: 0
Study 36350362 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36350468 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent onset dyspnoea (< 24 h)
Number of subjects: 1365
Study 36350468 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest pain
Number of subjects: 1365
Study 36350468 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleuritic pain
Number of subjects: 1365
Study 36350468 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlebitis
Number of subjects: 1365
Study 36350468 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic
Number of subjects: 1365
Study 36350598 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for Alcohol Use Disorder
Number of subjects: 0
Study 36350598 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 0
Study 36350899 — intervention group
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Number of subjects: 15
Study 36350899 — intervention group
Group type: COMPARATOR
Intervention: cabazitaxel chemotherapy
Number of subjects: 15
Study 36350983 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-protective ventilation
Number of subjects: 0
Study 36350983 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 36351064 — intervention group
Group type: EXPERIMENTAL
Intervention: Welch Allyn Connex® Spot Monitor/Hillrom Connecta™ automated solution
Number of subjects: 216
Study 36351064 — intervention group
Group type: COMPARATOR
Intervention: Usual routine (manual activation)
Number of subjects: 216
Study 36351188 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted verifiable subcision (TVS) using the Avéli device
Number of subjects: 0
Study 36351188 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 0
Study 36351402 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-specific p110β deficiency
Number of subjects: 0
Study 36351402 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic inhibition of p110β with TGX-221
Number of subjects: 0
Study 36351402 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet p110β
Number of subjects: 0
Study 36351402 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic deficiency or inhibition of platelet p110β
Number of subjects: 0
Study 36351430 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent plasma (CCP) therapy
Number of subjects: 0
Study 36351712 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with myocardial infarction
Number of subjects: 9551
Study 36351712 — intervention group
Group type: COMPARATOR
Intervention: Men with myocardial infarction
Number of subjects: 9551
Study 36351716 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI by advanced MRI techniques (diffusion tensor, cerebral perfusion, functional MRI, cerebral volumetry and cortical thickness, spectroscopy, susceptibility imaging)
Number of subjects: 0
Study 36351716 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological tests
Number of subjects: 0
Study 36351716 — intervention group
Group type: COMPARATOR
Intervention: High-level athletes not exposed to head impacts
Number of subjects: 0
Study 36351728 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil dose titration
Number of subjects: 0
Study 36351728 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36351741 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB) with 30 mL 2.5 mg/mL ropivacaine and 0.3 mL gadolinium.
Number of subjects: 10
Study 36351814 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (IVT) and/or endovascular treatment (EVT)
Number of subjects: 15
Study 36351919 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 patients with severe Neuro-COVID
Number of subjects: 0
Study 36351919 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 patients with plasma cytokine storm
Number of subjects: 0
Study 36351919 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-acute COVID-19 syndrome patients
Number of subjects: 0
Study 36351919 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 patients
Number of subjects: 0
Study 36351931 — intervention group
Group type: EXPERIMENTAL
Intervention: CoVLP+AS03 vaccine (3.75 µg CoVLP/dose + AS03), administered as two intramuscular doses, 21 days apart.
Number of subjects: 753
Study 36352028 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8931 (160 mg bd) with FOLFIRI
Number of subjects: 18
Study 36352054 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprocitentan 25 mg single oral dose
Number of subjects: 17
Study 36352054 — intervention group
Group type: COMPARATOR
Intervention: Matched healthy subjects (n=8 after one subject discontinued)
Number of subjects: 17
Study 36352103 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mL t.i.d. treatment with a full-spectrum, high-CBD sublingual solution (9.97 mg/mL CBD, 0.23 mg/mL Δ-9-tetrahydrocannabinol)
Number of subjects: 14
Study 36352322 — intervention group
Group type: EXPERIMENTAL
Intervention: CT/NG screening program offered annually from January 2018
Number of subjects: 234
Study 36352423 — intervention group
Group type: EXPERIMENTAL
Intervention: EIT (Electrical Impedance Tomography) during resting breathing
Number of subjects: 33
Study 36352423 — intervention group
Group type: EXPERIMENTAL
Intervention: EIT (Electrical Impedance Tomography) during forced expiration
Number of subjects: 33
Study 36352423 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical examination
Number of subjects: 33
Study 36352423 — intervention group
Group type: COMPARATOR
Intervention: PFT (Pulmonary Function Tests), FENO, IOS
Number of subjects: 33
Study 36352455 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) combined with ruxolitinib
Number of subjects: 21
Study 36353027 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior sex therapy (CBST)
Number of subjects: 0
Study 36353230 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity assessed by body mass index (BMI)
Number of subjects: 0
Study 36353571 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenegermin
Number of subjects: 5
Study 36353661 — intervention group
Group type: EXPERIMENTAL
Intervention: abiraterone acetate plus prednisone (ABI-DOCE)
Number of subjects: 3003
Study 36353661 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel (DOCE)
Number of subjects: 3003
Study 36353661 — intervention group
Group type: EXPERIMENTAL
Intervention: enzalutamide (ENZA)
Number of subjects: 3003
Study 36353661 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatment sequences including ABI-DOCE, ABI-ENZA, ABI-RAD, DOCE-ABI, DOCE-CABA, DOCE-ENZA, ENZA-DOCE
Number of subjects: 3003
Study 36353661 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 3003
Study 36353697 — intervention group
Group type: EXPERIMENTAL
Intervention: haMSter app for monitoring patient reported outcomes (PROs)
Number of subjects: 50
Study 36354082 — intervention group
Group type: EXPERIMENTAL
Intervention: FB2001
Number of subjects: 0
Study 36355054 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8205 (3.5 mg/kg single administration)
Number of subjects: 26
Study 36355054 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD5305 (in combination with AZD8205)
Number of subjects: 26
Study 36355259 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation with Tumor Treating Fields (TTFields, 200 kHz), standard concurrent temozolomide (TMZ), and scalp-sparing radiation (60 Gy in 30 fractions). Maintenance therapy included standard TMZ and continuation of TTFields.
Number of subjects: 30
Study 36355406 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention (9-module course comprising psychoeducation and home practice)
Number of subjects: 1754
Study 36355406 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 1754
Study 36355613 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Hypertension (cHTN)
Number of subjects: 100
Study 36355613 — intervention group
Group type: COMPARATOR
Intervention: Normotensive Gravidas
Number of subjects: 100
Study 36355639 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention designed to increase PAP adherence delivered via telehealth.
Number of subjects: 17
Study 36355650 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent involvement CBT targeting negative reinforcement
Number of subjects: 211
Study 36355650 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent involvement CBT targeting psychological control
Number of subjects: 211
Study 36355650 — intervention group
Group type: COMPARATOR
Intervention: Individual-youth CBT
Number of subjects: 211
Study 36355684 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaping as usual
Number of subjects: 30
Study 36355684 — intervention group
Group type: COMPARATOR
Intervention: Short-term nicotine deprivation (16 hr)
Number of subjects: 30
Study 36355754 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 cohort
Number of subjects: 157134
Study 36355775 — intervention group
Group type: EXPERIMENTAL
Intervention: M72/AS01 vaccine (two immunizations)
Number of subjects: 3
Study 36356042 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (375 mg/day)
Number of subjects: 86
Study 36356042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 36356184 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening modality (not specified)
Number of subjects: 0
Study 36356184 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast density (not specified)
Number of subjects: 0
Study 36356235 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine orthostatic hypotension assessment
Number of subjects: 0
Study 36356235 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated orthostatic hypotension assessment
Number of subjects: 0
Study 36356235 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls and orthostatic symptoms
Number of subjects: 0
Study 36356418 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal mammary chain radiation therapy (RT)
Number of subjects: 3295
Study 36356418 — intervention group
Group type: EXPERIMENTAL
Intervention: Normofractionated radiation therapy (RT)
Number of subjects: 3295
Study 36356599 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-viral precision T cell receptor replacement
Number of subjects: 0
Study 36356684 — intervention group
Group type: EXPERIMENTAL
Intervention: Baveno VII algorithm with SSM@50 Hz
Number of subjects: 504
Study 36356684 — intervention group
Group type: EXPERIMENTAL
Intervention: Baveno VII algorithm with SSM@100 Hz
Number of subjects: 504
Study 36356684 — intervention group
Group type: COMPARATOR
Intervention: Other measures (LSM-longitudinal spleen diameter to platelet ratio score)
Number of subjects: 504
Study 36356684 — intervention group
Group type: COMPARATOR
Intervention: Other measures (platelet count/longitudinal spleen diameter ratio)
Number of subjects: 504
Study 36356684 — intervention group
Group type: COMPARATOR
Intervention: Other measures (Rete Sicilia Selezione Terapia-hepatitis)
Number of subjects: 504
Study 36356712 — intervention group
Group type: EXPERIMENTAL
Intervention: dupilumab/dupilumab
Number of subjects: 1530
Study 36356712 — intervention group
Group type: COMPARATOR
Intervention: placebo/dupilumab
Number of subjects: 1530
Study 36356959 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute myocardial infarction (AMI)
Number of subjects: 168
Study 36356959 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic stenosis (AS)
Number of subjects: 168
Study 36356959 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 168
Study 36356972 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 80 mg as a continuous daily infusion for 8 days followed by slow tapering
Number of subjects: 677
Study 36356972 — intervention group
Group type: COMPARATOR
Intervention: Conventional dexamethasone (6 mg daily for 7-10 days)
Number of subjects: 677
Study 36357018 — intervention group
Group type: EXPERIMENTAL
Intervention: Amulet device
Number of subjects: 1833
Study 36357018 — intervention group
Group type: COMPARATOR
Intervention: Watchman device
Number of subjects: 1833
Study 36357087 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency renal denervation (RDN)
Number of subjects: 3077
Study 36357133 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-attenuation plaque burden above the median
Number of subjects: 404
Study 36357133 — intervention group
Group type: EXPERIMENTAL
Intervention: GRACE score >140
Number of subjects: 404
Study 36357133 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive coronary artery disease
Number of subjects: 404
Study 36357133 — intervention group
Group type: EXPERIMENTAL
Intervention: Total plaque burden
Number of subjects: 404
Study 36357133 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncalcified plaque burden
Number of subjects: 404
Study 36357133 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-attenuation plaque burden
Number of subjects: 404
Study 36357295 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciltacabtagene autoleucel (cilta-cel) therapy
Number of subjects: 36
Study 36357392 — intervention group
Group type: EXPERIMENTAL
Intervention: Branaplam (splicing modulator)
Number of subjects: 0
Study 36357415 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant camrelizumab plus concurrent chemoradiotherapy
Number of subjects: 36
Study 36357790 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-operative management (initial strategy in 152 patients, 48.1%)
Number of subjects: 316
Study 36357790 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgent surgery (performed in 164 patients, 51.9%)
Number of subjects: 316
Study 36357790 — intervention group
Group type: EXPERIMENTAL
Intervention: Entire cohort
Number of subjects: 316
Study 36357877 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP awareness influenced by external factors such as social media and community knowledge about HIV treatment and prevention.
Number of subjects: 25
Study 36357877 — intervention group
Group type: EXPERIMENTAL
Intervention: Joining the HIV vaccine trial preparedness study.
Number of subjects: 25
Study 36357877 — intervention group
Group type: EXPERIMENTAL
Intervention: Community perceptions of PrEP usage.
Number of subjects: 25
Study 36357877 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding barriers to PrEP uptake.
Number of subjects: 25
Study 36357881 — intervention group
Group type: EXPERIMENTAL
Intervention: MINDxYOU online intervention
Number of subjects: 180
Study 36357934 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led clinic targeting symptom management through a trigger alert system, utilizing electronic patient-reported outcome (ePRO) assessments at baseline, and 2, 4, 6, 8, 10, and 12 months, including input from a dietitian monitoring diet and nutritional status.
Number of subjects: 200
Study 36357934 — intervention group
Group type: COMPARATOR
Intervention: Usual care pathway standard of care, attending the cancer survivorship clinic and completing ePRO assessments at the start and end of the study.
Number of subjects: 200
Study 36357949 — intervention group
Group type: EXPERIMENTAL
Intervention: Giving birth during the pandemic
Number of subjects: 12133
Study 36357949 — intervention group
Group type: COMPARATOR
Intervention: Giving birth before the pandemic
Number of subjects: 12133
Study 36358012 — intervention group
Group type: EXPERIMENTAL
Intervention: VPM1002
Number of subjects: 2064
Study 36358012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2064
Study 36358277 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive immune age metric
Number of subjects: 597
Study 36358277 — intervention group
Group type: COMPARATOR
Intervention: Chronological age
Number of subjects: 597
Study 36358277 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity and physical activity
Number of subjects: 597
Study 36358642 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated method (AM) for calculating metabolic tumor volume (MTV)
Number of subjects: 100
Study 36358694 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-emptive Lymphocytes-apheresis
Number of subjects: 14
Study 36358694 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care Lymphocytes-apheresis
Number of subjects: 14
Study 36358702 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium electroporation (CaEP) with intratumoral injection of calcium gluconate followed by reversible electroporation.
Number of subjects: 8
Study 36358702 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium electroporation (CaEP) treatment.
Number of subjects: 8
Study 36358930 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide (TRZD), a GLP-1 and GIP agonist, used as an anti-diabetic drug.
Number of subjects: 0
Study 36358930 — intervention group
Group type: COMPARATOR
Intervention: Anti-diabetic/glucose-lowering drugs (general category).
Number of subjects: 0
Study 36360424 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 159
Study 36360424 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 159
Study 36360424 — intervention group
Group type: COMPARATOR
Intervention: Polytherapy
Number of subjects: 159
Study 36360619 — intervention group
Group type: COMPARATOR
Intervention: Push-ups on stable surface (PS)
Number of subjects: 51
Study 36360619 — intervention group
Group type: EXPERIMENTAL
Intervention: Push-ups on monopodal surface (PM)
Number of subjects: 51
Study 36360619 — intervention group
Group type: EXPERIMENTAL
Intervention: Push-ups on rings (PR)
Number of subjects: 51
Study 36360619 — intervention group
Group type: EXPERIMENTAL
Intervention: Push-ups on TRX
Number of subjects: 51
Study 36360766 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy sleep programme sessions (2 sessions)
Number of subjects: 60
Study 36360766 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 60
Study 36361102 — intervention group
Group type: EXPERIMENTAL
Intervention: Athens Insomnia Scale (AIS)
Number of subjects: 200
Study 36362554 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Barthel index
Number of subjects: 355
Study 36362554 — intervention group
Group type: EXPERIMENTAL
Intervention: Low grip strength
Number of subjects: 355
Study 36362554 — intervention group
Group type: EXPERIMENTAL
Intervention: Low physical activity level
Number of subjects: 355
Study 36362599 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraglottic airway devices (SGA)
Number of subjects: 343
Study 36362599 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation (ETI)
Number of subjects: 343
Study 36362730 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI) in non-calcific aortic stenosis patients
Number of subjects: 328
Study 36362730 — intervention group
Group type: COMPARATOR
Intervention: Transcatheter aortic valve implantation (TAVI) in calcific aortic stenosis patients
Number of subjects: 328
Study 36364763 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive individuals
Number of subjects: 989
Study 36364763 — intervention group
Group type: COMPARATOR
Intervention: Normotensive controls
Number of subjects: 989
Study 36366796 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0
Study 36367058 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 66
Study 36367058 — intervention group
Group type: COMPARATOR
Intervention: Other antiplatelets
Number of subjects: 66
Study 36367058 — intervention group
Group type: COMPARATOR
Intervention: No antiplatelets or poor compliance
Number of subjects: 66
Study 36367100 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion injury (RORI) observed via imaging after recanalization
Number of subjects: 23
Study 36367449 — intervention group
Group type: EXPERIMENTAL
Intervention: Twinkle marker
Number of subjects: 8
Study 36367449 — intervention group
Group type: COMPARATOR
Intervention: Radioactive seed
Number of subjects: 8
Study 36367449 — intervention group
Group type: COMPARATOR
Intervention: Biopsy clip
Number of subjects: 8
Study 36367600 — intervention group
Group type: EXPERIMENTAL
Intervention: SASP proteins (Activin A, ICAM1, MMP7, VEGFA, eotaxin)
Number of subjects: 1377
Study 36367600 — intervention group
Group type: EXPERIMENTAL
Intervention: SASP proteins (PARC, ADAMTS13, RANTES in females; MMP2, SOST, MCP1 in males)
Number of subjects: 1377
Study 36367717 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine uptake
Number of subjects: 0
Study 36367759 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based training course on pediatric palliative care (PPC) for 2 weeks through the Relais Platform.
Number of subjects: 172
Study 36367759 — intervention group
Group type: COMPARATOR
Intervention: Usual care without additional training.
Number of subjects: 172
Study 36367769 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity training
Number of subjects: 80
Study 36367769 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-to-moderate intensity training
Number of subjects: 80
Study 36367769 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no supervised training)
Number of subjects: 80
Study 36367894 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL-PET/CT
Number of subjects: 50
Study 36367894 — intervention group
Group type: EXPERIMENTAL
Intervention: Next generation sequencing of tumors
Number of subjects: 50
Study 36368038 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-valent pneumococcal conjugate vaccine
Number of subjects: 0
Study 36368073 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysomnography (PSG) on two nights
Number of subjects: 32
Study 36368073 — intervention group
Group type: COMPARATOR
Intervention: Nights with PSG
Number of subjects: 32
Study 36368073 — intervention group
Group type: COMPARATOR
Intervention: Nights without PSG
Number of subjects: 32
Study 36368073 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of PSG variables between the two PSG nights
Number of subjects: 32